Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia
作者:Cristina Torres-Fuentes、Elena Pastor-Cavada、Rafael Cano、Dalia Kandil、Rachel Shanahan、Rocio Juan、Hamdy Shaban、Gerard McGlacken、Harriët Schellekens
DOI:10.3390/ijms19061605
日期:——
Cachexia is a metabolic wasting disorder characterized by progressive weight loss, muscle atrophy, fatigue, weakness, and appetite loss. Cachexia is associated with almost all major chronic illnesses including cancer, heart failure, obstructive pulmonary disease, and kidney disease and significantly impedes treatment outcome and therapy tolerance, reducing physical function and increasing mortality
恶病质是一种代谢性消耗障碍,其特征在于进行性的体重减轻,肌肉萎缩,疲劳,虚弱和食欲不振。恶病质与几乎所有主要的慢性疾病有关,包括癌症,心力衰竭,阻塞性肺疾病和肾脏疾病,并显着阻碍治疗结果和治疗耐受性,降低身体机能并增加死亡率。当前恶病质的治疗是有限的,并且需要新的药理学策略。生长激素促分泌素(GHS-R1a)或促生长素释放肽受体的激动剂,前瞻性地调节食欲和生长激素分泌的中枢调节,因此具有作为恶病质治疗剂的巨大潜力。非肽GHS-R1a激动剂特别令人感兴趣,特别是考虑到基于肽的结构在胃肠道中的高度降解,包括内源性配体生长激素释放肽的生长,其半衰期仅为30分钟。但是,文献中几乎没有化合物作为非肽GHS-R1a激动剂被报道。在本文中,我们研究了喹诺酮类化合物在体外转染的人细胞和小鼠下丘脑细胞中调节GHS-R1a的体外潜力。这些化学合成的化合物显示出作为GHS-R1a激动剂的潜力,表现为细胞内钙内流